United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 4 mg - doxazosin tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin tablets may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin tablet monotherapy. doxazosin tablets provide rapid improvement in symptoms and urinary flow rate in 66% to 71% of patients. sustained improvements with doxazosin tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. doxazosin tablets are also indicated for the treatment of hypertension. doxazosin tablets may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute otitis m

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e) - metronidazole 500 mg - symptomatic trichomoniasis metronidazole tablets usp are indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). asymptomatic trichomoniasis metronidazole tablets usp are indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. treatment of asymptomatic consorts t. vaginalis infection is a venereal disease. therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. the decision as to whether to treat an asymptomatic male partner who has a negative culture

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - cefprozil (unii: 4w0459za4v) (cefprozil anhydrous - unii:1m698f4h4e) - cefprozil anhydrous 500 mg - cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: caused by streptococcus pyogenes . note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefprozil is generally effective in the eradication of streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. caused by streptococcus pneumoniae, haemophilus influenzae (including ß-lactamase-producing strains), and moraxella (branhamella) catarrhalis (including ß-lactamase-producing strains). (see clinical studies.) note: in the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observe

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - cefdinir (unii: ci0fao63wc) (cefdinir - unii:ci0fao63wc) - cefdinir 125 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. community-acquired pneumonia caused by haemophilus influenzae (including β-lactamase producing strains), haemophilus parainfluenzae (including β-lactamase producing strains), streptococcus pneumoniae (penicillin-susceptible strains only), and moraxella catarrhalis (including β-lactamase pr

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 200 mg - fluconazole tablets usp are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of candida urinary tract infections, peritonitis, and systemic candida infections including candidemia, disseminated candidiasis, and pneumonia. - cryptococcal meningitis. before prescribing fluconazole for aids patients with cryptococcal meningitis, please see clinical studies section. studies comparing fluconazole to amphotericin b in non-hiv infected patients have not been conduct fluconazole tablets usp are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and id

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - eszopiclone (unii: uzx80k71oe) (eszopiclone - unii:uzx80k71oe) - eszopiclone 2 mg - eszopiclone tablets are indicated for the treatment of insomnia. in controlled outpatient and sleep laboratory studies, eszopiclone administered at bedtime decreased sleep latency and improved sleep maintenance.   the clinical trials performed in support of efficacy were up to 6 months in duration. the final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only). eszopiclone tablets are contraindicated in patients with known hypersensitivity to eszopiclone. hypersensitivity reactions include anaphylaxis and angioedema [see warnings and precautions (5.3) ]. pregnancy category c there are no adequate and well-controlled studies in pregnant women. eszopiclone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.   oral administration of eszopiclone to pregnant rats (62.5, 125, or 250 mg/kg/day) and rabbits (

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules, usp are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - oseltamivir phosphate (unii: 4a3o49ngez) (oseltamivir carboxylate - unii:k6106lv5q8) - oseltamivir carboxylate 75 mg - oseltamivir phosphate capsules, usp is indicated for the treatment of acute, uncomplicated illness due to influenza a and b infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. oseltamivir phosphate is indicated for the prophylaxis of influenza a and b in patients 1 year and older. - oseltamivir phosphate capsules is not a substitute for early influenza vaccination on an annual basis as recommended by the centers for disease control and prevention advisory committee on immunization practices. - influenza viruses change over time. emergence of resistance substitutions could decrease drug effectiveness. other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see microbiology (12.4)]. -  oseltamivir phosphate capsules is not recommended f

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin anhydrous 250 mg in 5 ml - cephalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and s. pyogenes . (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to s. pneumoniae, h. influenzae , staphylococci, streptococci, and m. catarrhalis . skin and skin structure infections caused by staphylococci and/or streptococci. bone infections caused by staphylococci and/or p. mirabilis . genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and k. pneumoniae. note – culture and susceptibility tests should be initiated prior to and